| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,956 |
3,748 |
$156K |
| 99215 |
Prolong outpt/office vis |
1,811 |
1,406 |
$58K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,933 |
2,445 |
$56K |
| 94010 |
|
3,303 |
2,541 |
$39K |
| 96112 |
|
1,048 |
839 |
$33K |
| 95012 |
|
3,342 |
2,544 |
$27K |
| 92081 |
|
3,045 |
2,505 |
$27K |
| 99078 |
|
2,865 |
2,069 |
$23K |
| 92552 |
|
2,814 |
2,293 |
$20K |
| 99000 |
|
6,403 |
2,225 |
$18K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,331 |
1,026 |
$15K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
394 |
314 |
$13K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
539 |
438 |
$12K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
446 |
328 |
$11K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,750 |
1,391 |
$9K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
272 |
237 |
$9K |
| 83655 |
|
959 |
909 |
$8K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,887 |
1,575 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,924 |
1,456 |
$7K |
| 95076 |
|
314 |
223 |
$6K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
889 |
833 |
$6K |
| 99441 |
|
266 |
216 |
$6K |
| 36406 |
|
1,253 |
415 |
$5K |
| 69210 |
|
677 |
482 |
$5K |
| 80061 |
Lipid panel |
1,024 |
949 |
$5K |
| 98960 |
|
8,701 |
4,722 |
$4K |
| 36410 |
|
2,134 |
869 |
$4K |
| 99354 |
|
1,079 |
771 |
$4K |
| 99205 |
Prolong outpt/office vis |
102 |
97 |
$4K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,975 |
991 |
$3K |
| 90671 |
|
13 |
13 |
$3K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
640 |
507 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
461 |
356 |
$2K |
| 90461 |
|
1,039 |
330 |
$2K |
| 96111 |
|
14 |
14 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
29 |
26 |
$1K |
| 87420 |
|
1,062 |
783 |
$880.82 |
| 15852 |
|
444 |
329 |
$718.34 |
| 94760 |
|
3,051 |
2,329 |
$714.44 |
| 87430 |
|
310 |
248 |
$708.10 |
| 99050 |
|
242 |
193 |
$628.10 |
| 84443 |
Thyroid stimulating hormone (TSH) |
128 |
114 |
$417.14 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
295 |
264 |
$385.15 |
| 99381 |
|
16 |
15 |
$364.40 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
30 |
26 |
$346.74 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
14 |
14 |
$291.30 |
| 80053 |
Comprehensive metabolic panel |
166 |
150 |
$238.55 |
| 99355 |
|
164 |
152 |
$215.44 |
| 99051 |
|
45 |
39 |
$179.34 |
| 81000 |
|
802 |
627 |
$178.52 |
| 93000 |
|
12 |
12 |
$161.64 |
| 86580 |
|
33 |
32 |
$109.50 |
| 94761 |
|
114 |
91 |
$76.65 |
| 90734 |
|
32 |
29 |
$75.00 |
| 90651 |
|
53 |
50 |
$75.00 |
| 83013 |
|
19 |
19 |
$69.85 |
| 85014 |
|
66 |
58 |
$63.80 |
| 80502 |
|
60 |
47 |
$58.94 |
| J7510 |
Prednisolone oral, per 5 mg |
56 |
54 |
$32.35 |
| 85018 |
|
22 |
20 |
$24.10 |
| 90688 |
|
100 |
100 |
$17.56 |
| 81003 |
|
60 |
47 |
$16.31 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
567 |
441 |
$13.47 |
| 96160 |
|
470 |
430 |
$9.28 |
| 82465 |
|
12 |
12 |
$8.75 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
491 |
407 |
$0.93 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
795 |
654 |
$0.58 |
| J7614 |
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg |
55 |
44 |
$0.24 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
64 |
52 |
$0.20 |
| 84439 |
|
71 |
59 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
118 |
102 |
$0.00 |
| 82570 |
|
60 |
47 |
$0.00 |
| 3725F |
|
15 |
14 |
$0.00 |
| 90633 |
|
46 |
42 |
$0.00 |
| 99358 |
Prolong nursin fac eval 15m |
93 |
76 |
$0.00 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
27 |
16 |
$0.00 |
| 86703 |
|
373 |
289 |
$0.00 |
| 99173 |
|
158 |
156 |
$0.00 |
| 81002 |
|
60 |
47 |
$0.00 |
| 90670 |
|
111 |
109 |
$0.00 |
| Q0177 |
Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
75 |
64 |
$0.00 |
| 90473 |
|
38 |
37 |
$0.00 |
| 4025F |
|
64 |
52 |
$0.00 |
| 87339 |
|
19 |
19 |
$0.00 |
| 80305 |
|
29 |
18 |
$0.00 |
| 4551F |
|
16 |
13 |
$0.00 |
| 90648 |
|
40 |
37 |
$0.00 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
12 |
12 |
$0.00 |
| 83525 |
|
18 |
13 |
$0.00 |
| 99359 |
Prolong nursin fac eval 15m |
18 |
18 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
12 |
12 |
$0.00 |
| 92283 |
|
678 |
634 |
$0.00 |
| 96127 |
|
224 |
206 |
$0.00 |
| 97802 |
|
545 |
500 |
$0.00 |
| 96161 |
|
129 |
121 |
$0.00 |
| 90680 |
|
62 |
61 |
$0.00 |
| 87073 |
|
40 |
33 |
$0.00 |
| 90686 |
|
141 |
134 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
141 |
123 |
$0.00 |
| 87084 |
|
64 |
51 |
$0.00 |
| J7626 |
Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg |
64 |
52 |
$0.00 |
| 1111F |
|
172 |
155 |
$0.00 |
| A9150 |
Non-prescription drugs |
808 |
579 |
$0.00 |
| 87071 |
|
41 |
34 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
14 |
12 |
$0.00 |
| 90723 |
|
62 |
60 |
$0.00 |
| 83009 |
|
19 |
19 |
$0.00 |
| 78268 |
|
19 |
19 |
$0.00 |
| 99403 |
|
13 |
13 |
$0.00 |
| 82962 |
|
13 |
13 |
$0.00 |
| 87070 |
|
40 |
33 |
$0.00 |
| 90647 |
|
14 |
14 |
$0.00 |